Nicole Pacchiarini

Nicole Pacchiarini

Auto-generated profile, based on publicly available information

Nicole Pacchiarini

Public Health Wales NHS Trust

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Cell
Verified
Journal Article
Open access
BJBen Jackson
Ben Jackson
MBMaciej F. Boni
Maciej F. Boni
MBMatthew J. Bull
Matthew J. Bull
ACAmy Colleran
Amy Colleran
RCRachel M. Colquhoun
Rachel M. Colquhoun
ARAndrew Rambaut
Andrew Rambaut
We present evidence for multiple independent origins of recombinant SARS-CoV-2 viruses sampled from late 2020 and early 2021 in the United Kingdom. Their genomes carry single nucleotide polymorphisms and deletions that are characteristic of the B.1.1.7 variant of concern, but lack the full complement of lineage-defining mutations. Instead, the remainder of their genomes share contiguous genetic variation with non-B.1.1.7 viruses circulating in the same geographic area at the same time as the recombinants. In four instances there was evidence for onward transmission of a recombinant-origin virus, including one transmission cluster of 45 sequenced cases over the course of two months. The inferred genomic locations of recombination breakpoints suggest that every community-transmitted recombinant virus inherited its spike region from a B.1.1.7 parental virus, consistent with a transmission advantage for B.1.1.7’s set of mutations.

4 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
EVErik M Volz
Erik M Volz
VHVerity Hill
Verity Hill
JMJohn T. McCrone
John T. McCrone
APAnna Price
Anna Price
DJDavid Jorgensen
David Jorgensen
TCThomas R. Connor
Thomas R. Connor
Summary: Global dispersal and increasing frequency of the SARS-CoV-2 Spike protein variant D614G are suggestive of a selective advantage but may also be due to a random founder effect. We investigate the hypothesis for positive selection of Spike D614G in the United Kingdom using more than 25,000 whole genome SARS-CoV-2 sequences. Despite the availability of a large data set, well represented by both Spike 614 variants, not all approaches showed a conclusive signal of positive selection. Population genetic analysis indicates that 614G increases in frequency relative to 614D in a manner consistent with a selective advantage. We do not find any indication that patients infected with the Spike 614G variant have higher COVID-19 mortality or clinical severity, but 614G is associated with higher viral load and younger age of patients. Significant differences in growth and size of 614G phylogenetic clusters indicate a need for continued study of this variant.

12 July 2022 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
NPNicole Pacchiarini
Nicole Pacchiarini
CSClare Sawyer
Clare Sawyer
CWChristopher Williams
Christopher Williams
DSDaryn Sutton
Daryn Sutton
CRChristopher Roberts
Christopher Roberts
CMCatherine Moore
Catherine Moore
Background: The Omicron (lineage B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was first reported in Wales, UK, on 3 December 2021. The aim of the study was to describe the first 1000 cases of the Omicron variant by demographic, vaccination status, travel and severe outcome status and compare this to contemporaneous cases of the Delta variant.Methods: Testing, typing and contact tracing data were collected by Public Health Wales and analysis undertaken by the Communicable Disease Surveillance Centre (CDSC). Risk ratios for demographic factors and symptoms were calculated comparing Omicron cases to Delta cases identified over the same time period.Results: By 14 December 2021, 1000 cases of the Omicron variant had been identified in Wales. Of the first 1000, just 3% of cases had a prior history of travel revealing rapid community transmission. A higher proportion of Omicron cases were identified in individuals aged 20–39, and most cases were double vaccinated (65.9%) or boosted (15.7%). Age‐adjusted analysis also revealed that Omicron cases were less likely to be hospitalised (0.4%) or report symptoms (60.8%). Specifically a significant reduction was observed in the proportion of Omicron cases reporting anosmia (8.9%).Conclusion: Key findings include a lower risk of anosmia and a reduced risk of hospitalisation in the first 1000 Omicron cases compared with co‐circulating Delta cases. We also identify that existing measures for travel restrictions to control importations of new variants identified outside the United Kingdom did not prevent the rapid ingress of Omicron within Wales.

30 May 2022 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
JAJames P. Adamson
James P. Adamson
CSChristopher Smith
Christopher Smith
NPNicole Pacchiarini
Nicole Pacchiarini
TCThomas Richard Connor
Thomas Richard Connor
JWJanet Wallsgrove
Janet Wallsgrove
HLHeather Lewis
Heather Lewis
Prisons are susceptible to outbreaks. Control measures focusing on isolation and cohorting negatively affect wellbeing. We present an outbreak of coronavirus disease 2019 (COVID-19) in a large male prison in Wales, UK, October 2020 to April 2021, and discuss control measures. We gathered case-information, including demographics, staff-residence postcode, resident cell number, work areas/dates, test results, staff interview dates/notes and resident prison-transfer dates. Epidemiological curves were mapped by prison location. Control measures included isolation (exclusion from work or cell-isolation), cohorting (new admissions and work-area groups), asymptomatic testing (case-finding), removal of communal dining and movement restrictions. Facemask use and enhanced hygiene were already in place. Whole-genome sequencing (WGS) and interviews determined the genetic relationship between cases plausibility of transmission. Of 453 cases, 53% (n = 242) were staff, most aged 25–34 years (11.5% females, 27.15% males) and symptomatic (64%). Crude attack-rate was higher in staff (29%, 95% CI 26–64%) than in residents (12%, 95% CI 9–15%). Whole-genome sequencing can help differentiate multiple introductions from person-to-person transmission in prisons. It should be introduced alongside asymptomatic testing as soon as possible to control prison outbreaks. Timely epidemiological investigation, including data visualisation, allowed dynamic risk assessment and proportionate control measures, minimising the reduction in resident welfare.

31 January 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
NPNicole Pacchiarini
Nicole Pacchiarini
CMCaoimhe McKerr
Caoimhe McKerr
MMMari Morgan
Mari Morgan
TCThomas R. Connor
Thomas R. Connor
CWChristopher Williams
Christopher Williams
\P\R\Nnicole Pacchiarini
\R\Nnicole Pacchiarini
The rapid detection and containment of healthcare-associated infections (HCAIs) is critical in preventing and controlling infectious disease outbreaks within healthcare settings. Whole genome sequencing (WGS) has emerged as a powerful tool for tracking the transmission dynamics of pathogens and when used alongside traditional epidemiological methods it can better inform our understanding of the pathogen origin, pathway and extent of transmission. Additionally, WGS can aid in identifying previously unrecognized reservoirs of infection, allowing for more effective control strategies and targeted interventions. This article describes the incorporation of WGS into infectious disease management in Wales and explores it in the context of COVID-19 and Clostridioides difficile. We also describe the developments made to the workforce in Wales to enable the expansion of WGS and reflect on the resources, infrastructure and training frameworks still required.

13 April 2023 in Microbial Genomics
Verified
Journal Article
Open access
NPNicole Pacchiarini
Nicole Pacchiarini
MCMichelle Cronin
Michelle Cronin
CSClare Sawyer
Clare Sawyer
CWCatie Williams
Catie Williams
ABAndrew Beazer
Andrew Beazer
CWChristopher Williams
Christopher Williams
Recombination, the process whereby a segment of genetic material from one genome is inserted into another, producing a new chimeric genome, is an important evolutionary mechanism frequently observed in coronaviruses. The risks posed by recombination include the shuffling of advantageous mutations that may increase transmissibility, severity or vaccine escape. We present a genomic and epidemiological description of a new recombinant lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), XR, first identified in Wales. The Pathogen Genomics Unit (Public Health Wales, UK) sequences positive SARS-CoV-2 PCR tests using the ARTIC SARS-CoV-2 sequencing protocol. Recombinants were detected using an in-house pipeline and the epidemiological data analysed in R. Nosocomial cases were defined as those with samples taken after >7 days in hospital. Between February and March 2022, we identified 78 samples with highly similar genomes, comprising a BA.1-like 5' end, a BA.2-like 3' end and a BA.2-like spike protein. This signature is consistent with recombination and was defined as XR by Pangolin (PANGO v1.8). A total of 50 % of cases had a sample collected whilst in hospital and the first three cases were immunocompromised patients. The patient median age was 58 years (range: 4–95 years) and most of the patients were fully vaccinated against SARS-CoV-2 (74 % third dose/booster). Three patients died within 28 days of their sample collection date, one of whom had COVID-19 listed amongst ICD10 (International Classification of Diseases 10) coded causes of death. Our integrated system enabled real-time monitoring of recombinant SARS-CoV-2 for early detection, in order to rapidly risk assess and respond. This work highlights the importance of setting-based surveillance of recombinant SARS-CoV-2, as well as the need to monitor immunocompromised populations through repeat testing and sequencing.